{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:06:37Z","timestamp":1784574397353,"version":"3.55.0"},"reference-count":34,"publisher":"SLACK, Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Surg Lasers Imaging Retina"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Objective:<\/jats:title>\n                    <jats:p>The CALM Registry was a retrospective cohort study that assessed real-world outcomes of treating chronic noninfectious uveitis affecting the posterior segment (NIU-PS) with the 0.18-mg fluocinolone acetonide implant (FAi).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Eligible participants were aged \u226518 years and diagnosed with chronic NIU-PS. Safety and effectiveness outcomes, as available, were collected from charts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Two hundred sixty-seven eyes from 200 participants received the FAi (mean age, 62.8 years; 10.5% phakic). Median intraocular pressure remained stable at 14.0 mmHg. Two cataract surgeries were reported. In the 12 months pre-FAi, 84.1% of eyes had \u22651 recurrence of uveitis; 12 months post-implant, the recurrence rate was 12.0%, and retinal thickness reduced significantly (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .05). The proportion of eyes with \u2265 20\/40 visual acuity was stable from baseline (49%) to 12 months (55%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Real-world data from the CALM Registry study indicate effective control of chronic NIU-PS with the FAi and no new safety signals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3928\/23258160-20260409-01","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:24:11Z","timestamp":1779366251000},"page":"362-368","source":"Crossref","is-referenced-by-count":0,"title":["One-year CALM Outcomes: Data From a Real-world Registry Study of the 0.18-mg Fluocinolone Acetonide Intravitreal Implant for the Treatment of Patients With Non-infectious Uveitis Affecting the Posterior Segment"],"prefix":"10.3928","volume":"57","author":[{"given":"Sumit","family":"Sharma","sequence":"first","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Y.","family":"Chang","sequence":"additional","affiliation":[{"name":"Massachusetts Eye Research &amp; Surgery Institution, Waltham, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene Y.","family":"Choi","sequence":"additional","affiliation":[{"name":"Texas Retina Associates, Dallas, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe","family":"Lin","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio;"},{"name":"Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, Oregon;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric B.","family":"Suhler","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, Oregon;"},{"name":"VA Portland Health Care System, Portland, Oregon;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison H.","family":"Zhao","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanika","family":"Seth","sequence":"additional","affiliation":[{"name":"Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[{"name":"Mass Eye and Ear, Mass General Brigham, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00163549"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.80.9.844"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.80.4.332"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-015-0128-9"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2016.3229"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2003.037226"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.695904"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.02.016"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2005.04.012"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.11.017"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00055735-200408000-00003"},{"key":"e_1_3_1_13_2","volume-title":"Prescribing information","author":"TRIESENCE","year":"2023","unstructured":"TRIESENCE. Prescribing information. Harrow; 2023. https:\/\/www.triesencehcp.com\/"},{"key":"e_1_3_1_14_2","volume-title":"Harrow completes transfer of the triesence new drug application","author":"Harrow","year":"2023","unstructured":"Harrow. Harrow completes transfer of the triesence new drug application. Harrow. November 29, 2023. https:\/\/investors.harrow.com\/news-releases\/news-release-details\/harrow-completes-transfer-triesencer-new-drug-application\/"},{"key":"e_1_3_1_15_2","volume-title":"Prescribing information","author":"OZURDEX","year":"2024","unstructured":"OZURDEX. Prescribing information. AbbVie; 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022315s009lbl.pdf"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.08.021"},{"key":"e_1_3_1_17_2","volume-title":"Prescribing information","author":"XIPERE","year":"2022","unstructured":"XIPERE. Prescribing information. Bausch & Lomb Americas Inc. 2022. https:\/\/www.xipere.com"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317560"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.01.006"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01314-y"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1041916"},{"key":"e_1_3_1_22_2","volume-title":"Prescribing information","author":"YUTIQ","year":"2023","unstructured":"YUTIQ. Prescribing information. Alimera Sciences, Inc. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210331Orig1s000Lbl.pdf"},{"key":"e_1_3_1_23_2","volume-title":"Prescribing information","author":"RETISERT","year":"2023","unstructured":"RETISERT. Prescribing information. Bausch & Lomb Americas, Inc. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021737s026lbl.pdf"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.04.030"},{"issue":"2025","key":"e_1_3_1_25_2","first-page":"26","article-title":"An update on local steroids for uveitis","volume":"22","author":"Arepalli S","year":"2025","unstructured":"Arepalli S. An update on local steroids for uveitis. Retinal Physician. 2025;22(July\/August 2025):26. https:\/\/retinalphysician.com\/issues\/2025\/julyaugust\/uveitis-corner\/","journal-title":"Retinal Physician"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2015.1114778"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00851-z"},{"key":"e_1_3_1_28_2","volume-title":"Prescribing information","author":"ILUVIEN","year":"2016","unstructured":"ILUVIEN. Prescribing information. Alimera Sciences, Inc. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/201923s000lbl.pdf"},{"key":"e_1_3_1_29_2","volume-title":"Ocular Surgery News","author":"DeFino A","unstructured":"DeFino A. FDA approves expanded label for Iluvien. Ocular Surgery News, Healio. Published March 14, 2025. https:\/\/www.healio.com\/news\/ophthalmology\/20250314\/fda-approves-expanded-label-for-iluvien"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.10.033"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.04.001"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181d87e04"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010469.pub4"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-022-00525-8"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.11.027"}],"container-title":["Ophthalmic Surgery, Lasers and Imaging Retina"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T18:56:47Z","timestamp":1784573807000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/23258160-20260409-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"alternative-id":["10.3928\/23258160-20260409-01"],"URL":"https:\/\/doi.org\/10.3928\/23258160-20260409-01","relation":{},"ISSN":["2325-8160","2325-8179"],"issn-type":[{"value":"2325-8160","type":"print"},{"value":"2325-8179","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}